Overview


According to FutureWise analysis the market for Obesity Treatment in 2023 is US$ 17.06 billion, and is expected to reach US$ 37.44 billion by 2031 at a CAGR of 10.30%.

A medical disease known as obesity is brought on by the body's fat cells expanding in size. This syndrome is linked to a number of health issues, such as diabetes, heart disease, high blood pressure, and several cancer types. Lack of sleep, inactivity, and excessive junk food intake are some of the key contributors to obesity. A healthy diet and regular exercise are thought to be the cornerstones of the treatment of obesity. It has been demonstrated that dietary modifications, increased physical activity, and behavioral adjustments can assist in improving the situation and stop several obesity-related health problems. Doctors may recommend specialized weight-loss methods and drugs in more severe situations. Orlistat (Xenical, Alli), naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), semaglutide (Wegovy), and others are well-known FDA-approved weight-loss medications.

For both advanced nations and lower- and middle-income economies, obesity is a major problem. According to the World Health Organisation report, obesity and overweight are linked to several diseases and have a higher mortality rate than undernourishment. A significant prevalence of chronic disorders, such as hypertension, diabetes, and orthopedic conditions, is reported in the overweight and obese population. Teenagers' weight increase is also a result of their changing preferences for sedentary lives, physical inactivity, and altered eating habits. The rise in obesity is expected to propel the market expansion.

A medical condition known as obesity is characterized by the body's fat cells growing in size. This syndrome has links to diabetes, high blood pressure, cardiovascular disease, and several types of cancer. Several factors, such as insufficient sleep, inactivity, and an excessive intake of junk food, bring on obesity. Rates of obesity have increased recently due to factors like the rise of the "work from home" trend, inactivity, unhealthy eating habits, and risky behaviors. As the tendency towards working from home has grown, as has inactivity, poor eating habits, obesity rates have increased. The widespread use of pre-packaged, ready-to-eat meals, for example, has significantly affected a large portion of the population. In accordance with the Institute for Health Metrics and Evaluation, about 30% of individuals worldwide are overweight or obese. The market for obesity treatment is anticipated to grow over the forecast period due to the rising incidence of obesity and its associated disorders. Moreover, the prevalence of obesity has increased significantly, and pharmaceutical therapy now poses a considerable threat to health. Focused treatment with single-agent antibody medications may lead to quicker results with improved therapeutic efficacy, according to studies in this area. It is projected that ongoing clinical trials and drug development by different market participants will boost the target market's revenue growth. However, in developing countries, weight loss surgery costs are not properly covered. Clinical studies are also delayed due to safety issues with pharmaceuticals for managing obesity, and only a few therapies hit the market. Particular drug formulations can bring on drug-induced cancer or cardiovascular disease. For instance, the FDA had requested Eisai to remove its weight-loss drug Belviq from the market after studies showed that users had a greater chance of developing cancer. Such incidents are predicted to impede market expansion.

FutureWise Market Research has published a report that provides an insightful analysis of obesity treatment market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the obesity treatment market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Medtronic
  • Ethicon (subsidiary of Johnson & Johnson)
  • Cousin Biotech
  • Enteromedics
  • USGI Medical
  • VIVUS
  • Arena Pharmaceuticals
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Allergan Plc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Surgery

  • Adjusting gastric Banding
  • Roux-en-Y Gastric Bypass
  • Sleeve gastrectomy
  • Biliopancreatic diversion with Duodenal Switch
  • Endoscopic Procedures

By Drugs

  • Appetite suppressants
  • Combination drugs
  • Malabsorption
  • Satiety drugs

By End User

  • Clinics
  • Hospitals
  • Beauty institutions

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The region's dominance is attributed to the rising prevalence of diabetes and hypertension and the overweight and obese population. Additionally, it is projected that the paradigm change towards less invasive techniques would boost the development of the North American market for obesity treatment. The demand for obesity treatment devices in the regional market is also projected to be driven by the continually expanding healthcare infrastructure and rising healthcare spending.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Obesity Treatment Market By Surgery, By Drugs, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Obesity Treatment Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Obesity Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Obesity Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Obesity Treatment Market, By Surgery Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Adjusting gastric Banding
        2. Roux-en-Y Gastric Bypass
        3. Sleeve gastrectomy
        4. Biliopancreatic diversion with Duodenal Switch
        5. Endoscopic Procedures

  • 8.   Obesity Treatment Market, By Drugs Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Appetite suppressants
        2. Combination drugs
        3. Malabsorption
        4. Satiety drugs

  • 9.   Obesity Treatment Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinics
        2. Hospitals
        3. Beauty institutions

  • 10.   North America Obesity Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
                 2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Obesity Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Obesity Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Obesity Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Medtronic
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Ethicon (subsidiary of Johnson and Johnson)
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Cousin Biotech
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Enteromedics
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. USGI Medical
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. VIVUS
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Arena Pharmaceuticals
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. F. Hoffmann-La Roche Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novo Nordisk A/S
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Allergan Plc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients